Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.
Supposedly, thyrocyte-specific transcripts such as thyroglobulin (Tg) and thyroid-stimulating hormone receptor (TSH-R) were proposed to be useful for the diagnosis of circulating tumour cells in patients suffering from differentiated thyroid carcinoma (DTC). However, several research groups reported blood-borne Tg transcripts in healthy individuals. This study determines in particular the origin of Tg mRNA in nucleated blood cells and analyses whether other tumour-associated sequences are absent in leukocytes, but widely expressed in DTC. Therefore, expression analyses for Tg, TSH-R, cytokeratin 19 (CK 19), human telomerase reverse transcriptase (hTERT) and oncofoetal fibronectin (onfFN) were carried out using cDNAs derived from (1) leukocyte fractions, (2) 18 follicular thyroid carcinomas (FTCs) and 48 papillary thyroid carcinomas (PTCs), and (3) leukocytes of two thyrocyte-depleted individuals treated for C-cell carcinoma of the thyroid. Expression of onfFN was additionally analysed by semiquantitative RT-PCR and by quantitative fluorescence-based real-time PCR. Tg and TSH-R expression was demonstrated not only in both athyroid individuals, but in all leukocyte subgroups tested, while hTERT was absent in resting CD4+ cells and only weakly expressed in the CD8+ group. CK 19 was notable in each leukocyte population except for resting CD14(+), as well as for activated and resting CD19+ cells. All blood cell fractions proved negative for onfFN mRNA, whereas its presence in thyroid carcinoma was 78/98% (FTC/PTC). Threshold cycle values were calculated at: porphobilinogen deaminase (PBGD) = 25.95+/-0.73 (FTC)/24.55+/-5.43 (PTC) (P = 0.2878); onfFN = 25.48+/-3.15 (FTC)/21.44+/-3.44 (PTC) (*P = 0.0001). Finally, onfFN transcripts were detected in blood samples of six out of nine patients with known DTC metastases, demonstrating a reliable assay functionality. We propose that real-time RT-PCR of onfFN mRNA is superior to other markers in monitoring minimal residual disease in DTC with regard to both assay sensitivity and specificity.
Hesse
E
E
Clinical Chemistry, Hannover University Medical School, Carl Neuberg Str. 1, D-30625 Hannover, Germany. EricHesse@aol.com
Musholt
P B
PB
Potter
E
E
Petrich
T
T
Wehmeier
M
M
von Wasielewski
R
R
Lichtinghagen
R
R
Musholt
T J
TJ
D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000175:diagnosis*; D015703:Antigens, CD / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000235:genetics; D002291:Carcinoma, Papillary / Q000097:blood / Q000175:diagnosis*; D002454:Cell Differentiation; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D005353:Fibronectins / Q000235:genetics; D006801:Humans; D007633:Keratins / Q000235:genetics / Q000378:metabolism; D018365:Neoplasm, Residual / Q000097:blood / Q000175:diagnosis*; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics / Q000378:metabolism; D011989:Receptors, Thyrotropin / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000235:genetics / Q000378:metabolism; D013954:Thyroglobulin / Q000235:genetics / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000097:blood / Q000175:diagnosis*
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D005353:Fibronectins; D012333:RNA, Messenger; D011989:Receptors, Thyrotropin; C121542:oncofetal fibronectin; D007633:Keratins; D013954:Thyroglobulin; D019098:Telomerase